Published in Laryngoscope on June 01, 1988
Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg (2008) 1.31
Sex prevalence of focal dystonias. J Neurol Neurosurg Psychiatry (1996) 0.95
Spread of primary dystonia in relation to initially affected region. J Neurol (2007) 0.90
The phenomenology and natural history of idiopathic lower cranial dystonia. J Clin Mov Disord (2014) 0.84
Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol (1997) 0.83
Coprevalence of tremor with spasmodic dysphonia: a case-control study. Laryngoscope (2011) 0.81
The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry (1993) 0.78
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia (2010) 4.24
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia (2010) 3.54
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
Therapeutic uses of botulinum toxin. N Engl J Med (1991) 2.95
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Ring finger testing in carpal tunnel syndrome: a comparative study of diagnostic utility. Muscle Nerve (1989) 2.21
Idiopathic cervical dystonia: clinical characteristics. Mov Disord (1991) 2.21
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Functional brain networks in DYT1 dystonia. Ann Neurol (1998) 2.14
Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology (1992) 2.14
Oral and genital tardive pain syndromes. Neurology (1994) 2.07
What is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord (1991) 2.05
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 2.02
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol (1989) 2.00
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology (1994) 2.00
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 1.97
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology (1992) 1.93
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Botulinum toxin: dangerous terminology errors. J R Soc Med (1993) 1.91
Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. Ann Neurol (1990) 1.89
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord (1994) 1.88
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem (1966) 1.86
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. Am J Hum Genet (1991) 1.77
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 1.77
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Delayed-onset cerebellar syndrome. Arch Neurol (1996) 1.65
"Maximal" thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg (1988) 1.63
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. J Biol Chem (1966) 1.62
Chronic manganese intoxication. Arch Neurol (1974) 1.61
Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology (1990) 1.61
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Lymphoproliferative disorders and motor neuron disease: an update. Neurology (1997) 1.54
Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg (1993) 1.53
Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab (1993) 1.52
High dosage anticholinergic therapy in dystonia. Neurology (1983) 1.52
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol (1995) 1.51
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron (1989) 1.51
Polyglucosan body disease. Muscle Nerve (1991) 1.50
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 1.50
Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord (2000) 1.49
Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis. Is the tRNA(Leu(UUR)) gene an etiologic hot spot? J Clin Invest (1993) 1.48
A clinical and genetic study of chronic proximal spinal muscular atrophy. Brain (1975) 1.48
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol (2014) 1.47
Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology (1991) 1.46
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology (1981) 1.46
Strong allelic association between the torsion dystonia gene (DYT1) andloci on chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet (1992) 1.46
The clinical spectrum of posthypoxic myoclonus. Mov Disord (2000) 1.46
Movement disorder in reflex sympathetic dystrophy: a case proven to be psychogenic by surveillance video monitoring. Mov Disord (1997) 1.45
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology (1974) 1.44
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology (1979) 1.43
Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet (2004) 1.42
Welcome news about levodopa, but uncertainty remains. Ann Neurol (1998) 1.42
Regional distribution of gamma-aminobutyric acid (GABA) in brain of the rhesus monkey. J Neurochem (1968) 1.41
Tourette syndrome. Arch Neurol (1996) 1.39
Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology (1991) 1.39
Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology (1986) 1.38
Definition of dystonia and classification of the dystonic states. Adv Neurol (1976) 1.36
Prognosis of ocular myasthenia. Ann Neurol (1983) 1.35
Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol (1997) 1.34